Form 8-K Arcutis Biotherapeutics, For: Feb 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $11 at Goldman Sachs, 'Zoryve launches trending positively'
February 28, 2024 3:31 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $11.00 (from $6.00) while maintaining a Neutral rating.
The analyst comments "ARQT reported 4Q23 results with net Zoryve (roflumilast cream) sales in plaque psoriasis of $13.5mn, above our and Visible Alpha Consensus estimates of... More
